Trial Profile
A Phase I Trial of Interleukin-2 (Aldesleukin) and Pembrolizumab Combination Therapy for Patients With Advanced Renal Cell Carcinoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Renal cell carcinoma
- Focus Adverse reactions
- 16 Aug 2023 Status changed from recruiting to discontinued.
- 05 Oct 2022 Planned End Date changed from 17 Dec 2023 to 17 Dec 2024.
- 05 Oct 2022 Planned primary completion date changed from 17 Dec 2022 to 17 Dec 2023.